Novo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Novo Holdings and TA Associates have agreed to make an investment into Biocomposites.

After Novo Holdings acquires Catalent, it will sell three of the contract manufacturing giant’s sites to Novo Nordisk. Those facilities already make Novo Nordisk’s GLP-1 drugs for metabolic ...

HELLERUP, DENMARK, LONDON and KEELE, UK – 3 March 2025 – Novo Holdings and TA Associates ("TA"), announced today that the parties have entered into an agreement for Novo Holdings to make an investment ...

COPENHAGEN, Denmark, Jan. 10, 2025 /PRNewswire/ -- Novo Holdings, a leading life science investor, today announced that it has invested in a $200M Series A launch financing for Windward Bio.